Compare Cassava Sciences Inc (FLNA) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Zscaler Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Zscaler Inc trades at $146.14 (market cap $23.96B). The key difference: Zscaler Inc is far larger — about 450.9× Cassava Sciences Inc's market cap, and Zscaler Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | ZS | |
|---|---|---|
Market Cap | $53.14M | $23.96B |
Sector | Health | Technology |
52-Week High | $4.64 | $336.27 |
52-Week Low | $1.09 | $118.05 |
Enterprise Value | -$33.43M | $22.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Zscaler (ZS) trades at $146.75, down 3.51% on the day, with a bullish technical outlook supported by moving averages and key support at $145. The company shows strong revenue growth, reaching $2.67B in 2025, but remains unprofitable with a net margin of -2.44%. Recent quarters have consistently beaten EPS expectations, and analyst sentiment is overwhelmingly positive with 79% buy ratings.
ZS offers growth potential in cybersecurity with Zero Trust adoption and AI integration, but faces risks from profitability challenges, rising infrastructure costs, and legal investigations. The consensus price target of $192.64 implies significant upside, though investors must weigh strong demand against margin pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
